These findings support the potential clinical relevance of MDM2 and NF-κB in MM and emphasise the need for further investigation in larger cohorts with longer follow-up to better understand their role in disease biology, response to treatment and long-term outcomes. The gene discussed is NFKB1; the disease is Miyoshi myopathy.